ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 19, 2011 | $1,410,000 | Replaced |
| 3rd Quarter - Report | Jan 21, 2012 | $520,000 | Replaced |
| 3rd Quarter - Amendment | Feb 20, 2012 | $1,420,000 | Yes |
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Labor Issues/Antitrust/Workplace LBR
Discussions regarding possible clarifications to labor rules, including wage and hour issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| KIRSTEN POWELL | — |
Taxation/Internal Revenue Code TAX
Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
Copyright/Patent/Trademark CPT
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues. Discussions regarding global/free trade agreements and protection of intellectual property
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| BRADLEY ALLEN ROSSIN | — |
| HEATHER STRAWN | — |
Health Issues HCR
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| THERESA JOLIVETTE New | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| KIRSTEN POWELL | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY | — |
Medicare/Medicaid MMM
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| THERESA JOLIVETTE New | — |
| DANNY LY | — |
| KIRSTEN POWELL | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Consumer Issues/Safety/Products CSP
HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| HEATHER STRAWN | — |
Pharmacy PHA
HR 2112, HR 2190, S1206 - Proposed legislation regarding FDA appropriations FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| KIRSTEN POWELL | — |
| BRADLEY ALLEN ROSSIN | — |
| HEATHER STRAWN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.